Amarna Therapeutics appoints new CEO
Leiden-based Amarna Therapeutics announces the appointment of Dr Henk Streefkerk as the company's new Chief Executive Officer and Medical Director. Streefkerk has already been Amarna's Medical Director since mid-2022.
Dr Henk Streefkerk brings to Amarna extensive experience in clinical development, negotiations with health authorities and other regulatory interactions. He has a career as CMO of several biotech companies, including PIQUR Therapeutics, Cellprotera and Rivia, and has more than a decade of experience in the large pharmaceutical industry, including Novartis, Actelion and Organon. As a clinical pharmacologist/safety manager, he led the global product safety team, overseeing safety analyses, regulatory submissions and post-marketing safety surveillance for a heart failure drug. He was also instrumental in the approval of a cancer drug. Streefkerk began his medical career in otolaryngology and holds both an MD and PhD degree. As new CEO, he succeeds Steen Klysner, who has served as CEO for the past three years.
Amarna Therapeutics